<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The efficacy of bevacizumab combined with infusional <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi>/leucovorin (5-FU/LV) plus irinotecan (FOLFIRI) as the second-line treatment for <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC) has not been fully clarified, although bevacizumab combined with infusional 5-FU/LV plus <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (FOLFOX) in the second-line setting has demonstrated a survival benefit </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the efficacy of bevacizumab plus FOLFIRI in mCRC patients who failed <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-containing regimens without bevacizumab </plain></SENT>
<SENT sid="2" pm="."><plain>Patients who received bevacizumab plus FOLFIRI or bevacizumab plus FOLFOX as second-line chemotherapy between July 2007 and March 2008 were registered (trial registration: UMIN000001547) </plain></SENT>
<SENT sid="3" pm="."><plain>Patient background data and progression-free survival (PFS), overall survival (OS), response, and bevacizumab-related adverse events were prospectively collected every 6 months </plain></SENT>
<SENT sid="4" pm="."><plain>A total of 195 patients were enrolled from 26 institutions </plain></SENT>
<SENT sid="5" pm="."><plain>Among them, 115 patients received bevacizumab plus FOLFIRI after failure of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and fluoropyrimidine (FOLFIRI+BV after OX/FU group), and 45 patients received bevacizumab plus FOLFOX after failure of irinotecan and fluoropyrimidine (FOLFOX+BV after IRI/FU group) </plain></SENT>
<SENT sid="6" pm="."><plain>Median PFS was 8.3 months (95% confidence interval [CI], 6.7-9.9) for the FOLFIRI+BV after OX/FU group and 7.8 months (95% CI, 5.8-9.7) for the FOLFOX+BV after IRI/FU group </plain></SENT>
<SENT sid="7" pm="."><plain>Median OS was 21.6 months (95% CI, 17.6-25.6) and 16.5 months (95% CI, 11.8-21.2), respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Overall response rates were 25 and 29%, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>The most common gradeâ‰¥3 bevacizumab-related adverse events were <z:hpo ids='HP_0000822'>hypertension</z:hpo> (5.0%) and <z:mp ids='MP_0001914'>bleeding</z:mp> (3.8%) </plain></SENT>
<SENT sid="10" pm="."><plain>FOLFIRI+BV after OX/FU showed comparable efficacy to FOLFOX+BV after IRI/FU </plain></SENT>
</text></document>